vs
Side-by-side financial comparison of Canadian Solar Inc. (CSIQ) and Kenvue (KVUE). Click either name above to swap in a different company.
Canadian Solar Inc. is the larger business by last-quarter revenue ($4.5B vs $3.8B, roughly 1.2× Kenvue). Kenvue runs the higher net margin — 8.7% vs 1.3%, a 7.4% gap on every dollar of revenue.
Canadian Solar Inc. is a global renewable energy company. Headquartered in Kitchener, Ontario, the company manufactures solar PV modules, provides battery energy storage solutions and develops utility-scale solar power and battery energy storage projects.
Kenvue Inc. is an American consumer health company. Formerly the Consumer Healthcare division of Johnson & Johnson, Kenvue owns well-known brands such as Aveeno, Band-Aid, Benadryl, Combantrin, Zyrtec, Johnson's, Listerine, Lactaid, Mylanta, Neutrogena, Trosyd, Calpol, Tylenol, and Visine. Kenvue is incorporated in Delaware and was originally headquartered in the Skillman section of Montgomery Township, New Jersey, before relocating to Summit, New Jersey.
CSIQ vs KVUE — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $4.5B | $3.8B |
| Net Profit | $57.6M | $330.0M |
| Gross Margin | 17.5% | 56.5% |
| Operating Margin | 2.2% | 14.2% |
| Net Margin | 1.3% | 8.7% |
| Revenue YoY | — | 3.2% |
| Net Profit YoY | — | 12.6% |
| EPS (diluted) | — | $0.16 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $3.8B | ||
| Q3 25 | $4.5B | $3.8B | ||
| Q2 25 | $3.0B | $3.8B | ||
| Q1 25 | $1.3B | $3.7B | ||
| Q4 24 | — | $3.7B | ||
| Q3 24 | $5.9B | $3.9B | ||
| Q2 24 | $4.1B | $4.0B | ||
| Q1 24 | — | $3.9B |
| Q4 25 | — | $330.0M | ||
| Q3 25 | $57.6M | $398.0M | ||
| Q2 25 | $63.6M | $420.0M | ||
| Q1 25 | $36.2M | $322.0M | ||
| Q4 24 | — | $293.0M | ||
| Q3 24 | $366.8M | $383.0M | ||
| Q2 24 | $304.4M | $58.0M | ||
| Q1 24 | — | $296.0M |
| Q4 25 | — | 56.5% | ||
| Q3 25 | 17.5% | 59.1% | ||
| Q2 25 | 18.0% | 58.9% | ||
| Q1 25 | 19.0% | 58.0% | ||
| Q4 24 | — | 56.5% | ||
| Q3 24 | 18.0% | 58.5% | ||
| Q2 24 | 18.7% | 59.1% | ||
| Q1 24 | — | 57.6% |
| Q4 25 | — | 14.2% | ||
| Q3 25 | 2.2% | 16.7% | ||
| Q2 25 | 3.3% | 18.0% | ||
| Q1 25 | 3.7% | 14.9% | ||
| Q4 24 | — | 13.2% | ||
| Q3 24 | 7.7% | 16.8% | ||
| Q2 24 | 9.1% | 3.9% | ||
| Q1 24 | — | 14.1% |
| Q4 25 | — | 8.7% | ||
| Q3 25 | 1.3% | 10.6% | ||
| Q2 25 | 2.1% | 10.9% | ||
| Q1 25 | 2.7% | 8.6% | ||
| Q4 24 | — | 8.0% | ||
| Q3 24 | 6.2% | 9.8% | ||
| Q2 24 | 7.5% | 1.5% | ||
| Q1 24 | — | 7.6% |
| Q4 25 | — | $0.16 | ||
| Q3 25 | — | $0.21 | ||
| Q2 25 | — | $0.22 | ||
| Q1 25 | — | $0.17 | ||
| Q4 24 | — | $0.16 | ||
| Q3 24 | — | $0.20 | ||
| Q2 24 | — | $0.03 | ||
| Q1 24 | — | $0.15 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.7B | $1.1B |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $3.9B | $10.8B |
| Total Assets | $13.5B | $27.1B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $1.1B | ||
| Q3 25 | $1.7B | $1.1B | ||
| Q2 25 | $1.7B | $1.1B | ||
| Q1 25 | $1.7B | $1.1B | ||
| Q4 24 | — | $1.1B | ||
| Q3 24 | $1.9B | $1.1B | ||
| Q2 24 | $1.9B | $1.0B | ||
| Q1 24 | — | $1.2B |
| Q4 25 | — | $10.8B | ||
| Q3 25 | $3.9B | $10.6B | ||
| Q2 25 | $3.9B | $10.7B | ||
| Q1 25 | $3.9B | $10.1B | ||
| Q4 24 | — | $9.7B | ||
| Q3 24 | $3.7B | $10.6B | ||
| Q2 24 | $3.7B | $10.2B | ||
| Q1 24 | — | $10.6B |
| Q4 25 | — | $27.1B | ||
| Q3 25 | $13.5B | $27.2B | ||
| Q2 25 | $13.5B | $27.1B | ||
| Q1 25 | $13.5B | $26.3B | ||
| Q4 24 | — | $25.6B | ||
| Q3 24 | $11.9B | $26.9B | ||
| Q2 24 | $11.9B | $26.4B | ||
| Q1 24 | — | $27.3B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-187.7M | $854.0M |
| Free Cash FlowOCF − Capex | — | $744.0M |
| FCF MarginFCF / Revenue | — | 19.7% |
| Capex IntensityCapex / Revenue | — | 2.9% |
| Cash ConversionOCF / Net Profit | -3.26× | 2.59× |
| TTM Free Cash FlowTrailing 4 quarters | — | $1.7B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $854.0M | ||
| Q3 25 | $-187.7M | $294.0M | ||
| Q2 25 | — | $621.0M | ||
| Q1 25 | — | $428.0M | ||
| Q4 24 | — | $793.0M | ||
| Q3 24 | — | $249.0M | ||
| Q2 24 | — | $440.0M | ||
| Q1 24 | — | $287.0M |
| Q4 25 | — | $744.0M | ||
| Q3 25 | — | $196.0M | ||
| Q2 25 | — | $533.0M | ||
| Q1 25 | — | $249.0M | ||
| Q4 24 | — | $661.0M | ||
| Q3 24 | — | $190.0M | ||
| Q2 24 | — | $350.0M | ||
| Q1 24 | — | $134.0M |
| Q4 25 | — | 19.7% | ||
| Q3 25 | — | 5.2% | ||
| Q2 25 | — | 13.9% | ||
| Q1 25 | — | 6.7% | ||
| Q4 24 | — | 18.1% | ||
| Q3 24 | — | 4.9% | ||
| Q2 24 | — | 8.8% | ||
| Q1 24 | — | 3.4% |
| Q4 25 | — | 2.9% | ||
| Q3 25 | — | 2.6% | ||
| Q2 25 | — | 2.3% | ||
| Q1 25 | — | 4.8% | ||
| Q4 24 | — | 3.6% | ||
| Q3 24 | — | 1.5% | ||
| Q2 24 | — | 2.3% | ||
| Q1 24 | — | 3.9% |
| Q4 25 | — | 2.59× | ||
| Q3 25 | -3.26× | 0.74× | ||
| Q2 25 | — | 1.48× | ||
| Q1 25 | — | 1.33× | ||
| Q4 24 | — | 2.71× | ||
| Q3 24 | — | 0.65× | ||
| Q2 24 | — | 7.59× | ||
| Q1 24 | — | 0.97× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CSIQ
Segment breakdown not available.
KVUE
| Self Care | $1.6B | 42% |
| Essential Health | $1.1B | 30% |
| Skin Health And Beauty | $1.0B | 28% |
